JP5474033B2 - 置換イミダゾール誘導体を含む改良された製剤 - Google Patents
置換イミダゾール誘導体を含む改良された製剤 Download PDFInfo
- Publication number
- JP5474033B2 JP5474033B2 JP2011264745A JP2011264745A JP5474033B2 JP 5474033 B2 JP5474033 B2 JP 5474033B2 JP 2011264745 A JP2011264745 A JP 2011264745A JP 2011264745 A JP2011264745 A JP 2011264745A JP 5474033 B2 JP5474033 B2 JP 5474033B2
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- solid dosage
- rapidly
- formulation
- rapidly dispersible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
式(I)の化合物類およびそれらの塩は、それなりに良い性質をもっているが、従来の経口投与すなわち前記化合物を胃の中へ投与する通常の経路用に製剤された場合には欠点がある。これらの化合物は胃腸領域内でかなり急速に分解し、そのため問題の化合物の効果が大幅に低下することが分っている。
アチパメゾール(Atipamezole)(4-[1-(2,3-ジメチルフェニル)エチル]-1H-イミダゾールモノ塩酸塩)は、α2-アドレノセプター拮抗薬であり、本発明の化合物(I)の一例であるが、口腔内へのスプレーで投与すると経口投与に較べて生物学的利用能が高まることが示されている(R. Huupponenら、Clin. Pharmacol. Ther.、1995年、58巻506〜511頁)。吸収は、投与量に比例しないことが見出され(投与量を増加するにつれて相対的な吸収量は減少する)、また塗布部位に白斑や痺れなどの一時的な有害反応が観察された。
R1は、好ましくはハロゲン、より好ましくはフルオロ、最も好ましくは5-フルオロであり、
R2は、好ましくはHであり、
R3は、好ましくはエチルであり、
Yは、好ましくは-CH2-である。
1. ヒトにおける口腔内投与と経口投与の比較
胃前経路によって吸収が改善されることが、フィパメゾールを溶液として経口投与した場合と口腔内スプレーとして投与した場合との比較によって実証された。
健康な志願者(白人男性、年齢18〜35歳、体重60〜90kg)にフィパメゾールを投与量を増加させながら(0.5、1、3、9、18、30、60mg)溶液で経口投与した。各投与後に、薬物動力学的評価のために、間隔を置いて最長で24時間、血液サンプルを採取した。血漿中のフィパメゾールの濃度をHPLC-MS/MSで測定した。標準の安全性臨床検査、ECG(心電図)記録、血圧および心拍数測定ならびに有害事象の問診によって安全性と忍容性を評価した。
使用したプロトコールは、投与方法が口腔内スプレー(0.75、1.5、3、7.5、15、30、60、および90mg、一回投与)である点以外はほぼプロトコールAと同じであった。
この試験では、純粋種のビーグル犬(オス1匹およびメス1匹)にフィパメゾールを急速分散性錠剤(前記実施例3と同じ処方)(20mg/kg)として口腔経由で経口投与した。試験中(8日間、および試験前4日間)を通じて対象の生存能力、行動の変化、処置に対する反応および不健康状態について監視した。加えて、体重および食餌摂取量を記録した。血漿濃度分析(LC/MS/MS法)のために、投与の10、20、30、45分後および1、1.25、1.5、2、2.5、3、4、8時間後に血液を採取した。
2組のヒトの被験者に30mgのフィパメゾールを一回投与することによって、口腔内スプレーと急速溶解性剤形を直接比較した。上記の口腔内スプレーに関する所見とは対照的に、急速溶解性剤形では口腔の紅斑や白化は観察されず、したがって後者は患者の服薬遵守の点で有利である。これらの結果を表4に示す。表4を見れば分るように、急速溶解性錠剤の方が平均最大血漿濃度(Cmax)はより低かったが、標準偏差(SD)および変動係数(CV%)もより低かった。この効果は追試(被験者12人)においても確認され、CmaxのSDは口腔内スプレーおよび急速溶解性剤形でそれぞれ26.2および13.5であった。このより低いSDおよびCV%は、急速溶解性錠剤によって投与すれば目標とするCmaxの制御がより易しいものであり、したがって急速溶解性錠剤が患者の安全性の点で有利であることを示唆している。
Claims (16)
- 口腔内に置かれて10秒以内に崩壊するように製剤された、請求項1に記載の急速分散性固形剤形の製剤。
- 前記有効成分と、前記有効成分に対して不活性である水溶性または水分散性担体との網目構造を含むものであり、
前記網目構造は、溶媒中に前記有効成分と前記担体の溶液とを含む固体状態の組成物から溶媒を昇華させることによって得たものである、請求項2に記載の急速分散性固形剤形の製剤。 - 前記ゼラチンが魚ゼラチンである、請求項1に記載の急速分散性固形剤形の製剤。
- Yが-CH2-である、請求項1に記載の急速分散性固形剤形の製剤。
- R1がハロゲンまたはヒドロキシである、請求項1に記載の急速分散性固形剤形の製剤。
- R1がハロゲンである、請求項1に記載の急速分散性固形剤形の製剤。
- R1が5-ハロゲンである、請求項1に記載の急速分散性固形剤形の製剤。
- R1がフルオロである、請求項1に記載の急速分散性固形剤形の製剤。
- R2が水素である、請求項1に記載の急速分散性固形剤形の製剤。
- R3がC1〜C4アルキルである、請求項1に記載の急速分散性固形剤形の製剤。
- R3がエチルである、請求項1に記載の急速分散性固形剤形の製剤。
- 薬剤として許容可能な塩が酸付加塩である、請求項1に記載の急速分散性固形剤形の製剤。
- 薬剤として許容可能な塩が塩酸塩である、請求項13に記載の急速分散性固形剤形の製剤。
- 前記マトリックス形成剤が更にアミノ酸を含んでいる、請求項1に記載の急速分散性固形剤形の製剤。
- 前記アミノ酸がグリシンである、請求項15に記載の急速分散性固形剤形の製剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0226076.8A GB0226076D0 (en) | 2002-11-08 | 2002-11-08 | Improved formulations containing substituted imidazole derivatives |
GB0226076.8 | 2002-11-08 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004551671A Division JP2006517516A (ja) | 2002-11-08 | 2003-11-03 | 置換イミダゾール誘導体を含む改良された製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012051941A JP2012051941A (ja) | 2012-03-15 |
JP5474033B2 true JP5474033B2 (ja) | 2014-04-16 |
Family
ID=9947452
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004551671A Withdrawn JP2006517516A (ja) | 2002-11-08 | 2003-11-03 | 置換イミダゾール誘導体を含む改良された製剤 |
JP2011264745A Expired - Fee Related JP5474033B2 (ja) | 2002-11-08 | 2011-12-02 | 置換イミダゾール誘導体を含む改良された製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004551671A Withdrawn JP2006517516A (ja) | 2002-11-08 | 2003-11-03 | 置換イミダゾール誘導体を含む改良された製剤 |
Country Status (16)
Country | Link |
---|---|
US (1) | US9717681B2 (ja) |
EP (1) | EP1581192B1 (ja) |
JP (2) | JP2006517516A (ja) |
KR (1) | KR101170548B1 (ja) |
AU (1) | AU2003287476B2 (ja) |
CA (1) | CA2503630C (ja) |
ES (1) | ES2392967T3 (ja) |
GB (1) | GB0226076D0 (ja) |
HK (1) | HK1080282A1 (ja) |
IL (1) | IL168257A (ja) |
MX (1) | MXPA05004745A (ja) |
NO (1) | NO336460B1 (ja) |
NZ (1) | NZ539731A (ja) |
PL (1) | PL214226B1 (ja) |
RU (1) | RU2349305C2 (ja) |
WO (1) | WO2004043439A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004026769D1 (de) * | 2003-12-01 | 2010-06-02 | Sony Corp | Prozess zur herstellung eines originaldatenträgers für einen optischen datenträger und originaldatenträger für einen optischen datenträger |
US7972621B2 (en) * | 2004-06-03 | 2011-07-05 | R.P. Scherer Technologies, Llc | Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight |
US8268791B2 (en) | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
WO2011026080A1 (en) | 2009-08-31 | 2011-03-03 | Wilmington Pharmaceuticals, Llc | Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain |
MY150626A (en) | 2009-10-30 | 2014-02-07 | Ix Biopharma Ltd | Fast dissolving solid dosage form |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB211423A (en) | 1923-10-06 | 1924-02-21 | Leopold Seeger | Improved means for locking nuts |
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
IE45770B1 (en) * | 1976-10-06 | 1982-11-17 | Wyeth John & Brother Ltd | Pharmaceutical dosage forms |
NO852655L (no) | 1985-06-05 | 1986-12-08 | Bio Data Corp | Fremgangsmaate ved fremstilling av koaguleringsreagens for blodplasma i mikrokonsentrert tablettform. |
US4855326A (en) * | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
JPH02121919A (ja) * | 1988-10-28 | 1990-05-09 | Grelan Pharmaceut Co Ltd | 柔軟性を有する錠剤 |
GB2225782A (en) * | 1988-12-09 | 1990-06-13 | Farmos Group Limited | Imidazole derivatives useful for treatment of diabetes |
US4968692A (en) * | 1989-01-06 | 1990-11-06 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Attenuation of ethyl alcohol intoxication with alpha-2 adrenoceptor antagonists |
US4946684A (en) * | 1989-06-20 | 1990-08-07 | American Home Products Corporation | Fast dissolving dosage forms |
US5079018A (en) * | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
ATE145551T1 (de) | 1989-10-02 | 1996-12-15 | Cima Labs Inc | Brausedosisform sowie verfahren zu deren verabreichung |
GB9127050D0 (en) | 1991-12-20 | 1992-02-19 | Orion Yhtymae Oy | Substituted imidazole derivatives and their preparation and use |
HU219349B (en) | 1991-12-24 | 2001-03-28 | Yamanouchi Pharma Co Ltd | Intrabuccally disintegrating preparation and production thereof |
US5298261A (en) * | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
GB9312669D0 (en) * | 1993-06-18 | 1993-08-04 | Orion Yhtymae Oy | New opticla isomers |
US6726928B2 (en) * | 1994-10-28 | 2004-04-27 | R.P. Scherer Technologies, Inc. | Process for preparing solid dosage forms for unpalatable pharmaceuticals |
GB9517062D0 (en) * | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
JP3797387B2 (ja) | 1996-06-14 | 2006-07-19 | 協和醗酵工業株式会社 | 口腔内速崩壊錠 |
DE19646392A1 (de) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
US5976577A (en) * | 1997-07-11 | 1999-11-02 | Rp Scherer Corporation | Process for preparing fast dispersing solid oral dosage form |
FR2781152B1 (fr) | 1998-07-20 | 2001-07-06 | Permatec Tech Ag | Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation |
JP2000095674A (ja) * | 1998-09-22 | 2000-04-04 | Sato Pharmaceutical Co Ltd | 口腔内崩壊時間短縮化錠剤の製造方法及び装置 |
US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
GB9910505D0 (en) | 1999-05-06 | 1999-07-07 | Electrosols Ltd | A method and apparatus for manufacturing consumable tablets |
US6284270B1 (en) * | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
FR2798289B1 (fr) | 1999-09-15 | 2004-12-31 | Cll Pharma | Formes galeniques a delitement rapide en bouche et leur procede de preparation |
US6375982B1 (en) * | 2000-07-05 | 2002-04-23 | Capricorn Pharma, Inc. | Rapid-melt semi-solid compositions, methods of making same and method of using same |
CA2473975C (en) | 2001-10-12 | 2011-05-03 | Monosolrx Llc | Glucan based film delivery systems |
-
2002
- 2002-11-08 GB GBGB0226076.8A patent/GB0226076D0/en not_active Ceased
-
2003
- 2003-11-03 EP EP03781716A patent/EP1581192B1/en not_active Expired - Lifetime
- 2003-11-03 AU AU2003287476A patent/AU2003287476B2/en not_active Ceased
- 2003-11-03 KR KR1020057008248A patent/KR101170548B1/ko active IP Right Grant
- 2003-11-03 JP JP2004551671A patent/JP2006517516A/ja not_active Withdrawn
- 2003-11-03 NZ NZ539731A patent/NZ539731A/en not_active IP Right Cessation
- 2003-11-03 WO PCT/US2003/034934 patent/WO2004043439A1/en active Application Filing
- 2003-11-03 RU RU2005117626/15A patent/RU2349305C2/ru not_active IP Right Cessation
- 2003-11-03 ES ES03781716T patent/ES2392967T3/es not_active Expired - Lifetime
- 2003-11-03 PL PL375565A patent/PL214226B1/pl unknown
- 2003-11-03 CA CA2503630A patent/CA2503630C/en not_active Expired - Fee Related
- 2003-11-03 MX MXPA05004745A patent/MXPA05004745A/es active IP Right Grant
- 2003-11-03 US US10/534,117 patent/US9717681B2/en active Active
-
2005
- 2005-04-27 IL IL168257A patent/IL168257A/en active IP Right Grant
- 2005-05-12 NO NO20052360A patent/NO336460B1/no not_active IP Right Cessation
- 2005-11-11 HK HK05110140.3A patent/HK1080282A1/xx not_active IP Right Cessation
-
2011
- 2011-12-02 JP JP2011264745A patent/JP5474033B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HK1080282A1 (en) | 2006-04-21 |
NZ539731A (en) | 2008-06-30 |
EP1581192A4 (en) | 2009-12-02 |
JP2006517516A (ja) | 2006-07-27 |
RU2005117626A (ru) | 2006-01-20 |
AU2003287476A1 (en) | 2004-06-03 |
WO2004043439A1 (en) | 2004-05-27 |
ES2392967T3 (es) | 2012-12-17 |
AU2003287476B2 (en) | 2008-11-20 |
MXPA05004745A (es) | 2005-08-03 |
EP1581192A1 (en) | 2005-10-05 |
NO20052360L (no) | 2005-06-06 |
US20060134194A1 (en) | 2006-06-22 |
PL375565A1 (en) | 2005-11-28 |
EP1581192B1 (en) | 2012-08-08 |
NO336460B1 (no) | 2015-08-31 |
CA2503630C (en) | 2013-07-30 |
KR20050086458A (ko) | 2005-08-30 |
US9717681B2 (en) | 2017-08-01 |
JP2012051941A (ja) | 2012-03-15 |
CA2503630A1 (en) | 2004-05-27 |
IL168257A (en) | 2014-04-30 |
GB0226076D0 (en) | 2002-12-18 |
RU2349305C2 (ru) | 2009-03-20 |
PL214226B1 (pl) | 2013-07-31 |
KR101170548B1 (ko) | 2012-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5474033B2 (ja) | 置換イミダゾール誘導体を含む改良された製剤 | |
US7125564B2 (en) | Water soluble and palatable complexes | |
JP6294479B2 (ja) | 経口分散性フィルム | |
KR890002949B1 (ko) | 경구용 약제 조성물의 제조방법 | |
SK283597B6 (sk) | Farmaceutický prípravok na orálne podanie, spôsob jeho prípravy a jeho použitie, farmaceutický produkt a súprava | |
US7482377B2 (en) | Pharmaceutical compositions and methods of treatment based on diclofenac | |
BG103570A (bg) | Галенични форми и метод за подобряване на нарушената ерекция при мъже | |
BRPI0712353B1 (pt) | comprimidos sublinguais de analgésicos de opióide de dose baixa e processo de preparação | |
EP0814789B2 (en) | Pharmaceutical compositions comprising monoamine oxidase b inhibitors | |
WO2006133349A2 (en) | Orally disintegrable sleep aid formulations | |
JP2010501524A (ja) | アリスキレン用ガレヌス製剤 | |
WO2019186386A1 (en) | Melatonin oral dissolving film | |
US20110150974A1 (en) | Agent For Oral Mucosal Administration | |
WO1999038496A1 (en) | Fast dissolving pharmaceutical products | |
US20150072014A1 (en) | Pharmaceutical Compositions of Sodium Picosulfate, Magnesium Oxide and Citric Acid | |
JP2006070027A (ja) | 口腔粘膜投与剤 | |
JP2000508618A (ja) | 口腔乾燥症の処置におけるコリンエステラーゼ阻害剤の使用 | |
US20070087981A1 (en) | Water Soluble and Palatable Complexes | |
Nagpal et al. | Patent innovations in fast dissolving/disintegrating dosage forms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130806 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140204 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5474033 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |